Masitinib Shows Positive Signs in Progressive MS

(MedPage Today) -- Masitinib, an orally administered tyrosine kinase inhibitor targeting the innate immune system, showed positive signs in treating progressive forms of multiple sclerosis (MS) in the phase III AB07002 trial.
The drug, which specifically...